RAYVOWE Trademark

Trademark Overview


On Tuesday, September 26, 2017, a trademark application was filed for RAYVOWE with the United States Patent and Trademark Office. The USPTO has given the RAYVOWE trademark a serial number of 87622389. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 9, 2020. This trademark is owned by Eli Lilly and Company. The RAYVOWE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents a...
rayvowe

General Information


Serial Number87622389
Word MarkRAYVOWE
Filing DateTuesday, September 26, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 9, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 6, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, September 30, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, November 9, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 9, 2020ABANDONMENT - NO USE STATEMENT FILED
Saturday, March 21, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 19, 2020EXTENSION 4 GRANTED
Thursday, March 19, 2020EXTENSION 4 FILED
Thursday, March 19, 2020TEAS EXTENSION RECEIVED
Thursday, September 26, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 24, 2019EXTENSION 3 GRANTED
Tuesday, September 24, 2019EXTENSION 3 FILED
Tuesday, September 24, 2019TEAS EXTENSION RECEIVED
Thursday, February 28, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 26, 2019EXTENSION 2 GRANTED
Tuesday, February 26, 2019EXTENSION 2 FILED
Tuesday, February 26, 2019TEAS EXTENSION RECEIVED
Tuesday, September 18, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 17, 2018EXTENSION 1 GRANTED
Thursday, September 6, 2018EXTENSION 1 FILED
Monday, September 17, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, September 6, 2018TEAS EXTENSION RECEIVED
Tuesday, April 3, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 6, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 6, 2018PUBLISHED FOR OPPOSITION
Wednesday, January 17, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, December 22, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, December 15, 2017ASSIGNED TO EXAMINER
Saturday, September 30, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, September 29, 2017NEW APPLICATION ENTERED IN TRAM